CytomX Therapeutics shares are trading lower after the company reported Q4 financial results. Also, BMO Capital maintained a Market Perform rating on the stock and lowered its price target from $3.3 to $3.25.
Benzinga Newsdesk - Mar 12, 2024, 12:50PM